Dark Forest Capital Management LP Acquires Shares of 34,671 Enovis Co. (NYSE:ENOV)

Dark Forest Capital Management LP acquired a new stake in shares of Enovis Co. (NYSE:ENOV - Free Report) during the 2nd quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The firm acquired 34,671 shares of the company's stock, valued at approximately $1,567,000. Dark Forest Capital Management LP owned about 0.06% of Enovis at the end of the most recent reporting period.

Several other institutional investors and hedge funds have also recently modified their holdings of ENOV. GAMMA Investing LLC boosted its holdings in shares of Enovis by 19.9% in the 1st quarter. GAMMA Investing LLC now owns 1,085 shares of the company's stock worth $68,000 after purchasing an additional 180 shares during the period. Treasurer of the State of North Carolina lifted its holdings in shares of Enovis by 1.0% in the 4th quarter. Treasurer of the State of North Carolina now owns 23,252 shares of the company's stock worth $1,303,000 after acquiring an additional 220 shares during the last quarter. State of Michigan Retirement System boosted its stake in shares of Enovis by 2.5% during the 1st quarter. State of Michigan Retirement System now owns 12,202 shares of the company's stock worth $762,000 after purchasing an additional 300 shares during the period. Swiss National Bank raised its holdings in shares of Enovis by 0.3% in the first quarter. Swiss National Bank now owns 97,000 shares of the company's stock worth $6,058,000 after buying an additional 300 shares during the period. Finally, Benjamin F. Edwards & Company Inc. lifted its position in shares of Enovis by 28.1% during the second quarter. Benjamin F. Edwards & Company Inc. now owns 1,691 shares of the company's stock worth $76,000 after purchasing an additional 371 shares during the last quarter. Institutional investors own 98.45% of the company's stock.

Enovis Stock Up 2.2 %

Enovis stock traded up $0.94 during midday trading on Thursday, hitting $43.35. 509,192 shares of the company were exchanged, compared to its average volume of 555,373. The company has a market cap of $2.42 billion, a PE ratio of -28.27 and a beta of 1.92. The company's fifty day moving average price is $44.55 and its 200-day moving average price is $49.56. The company has a debt-to-equity ratio of 0.40, a current ratio of 2.26 and a quick ratio of 1.08. Enovis Co. has a fifty-two week low of $39.98 and a fifty-two week high of $65.03.

Enovis (NYSE:ENOV - Get Free Report) last announced its earnings results on Wednesday, August 7th. The company reported $0.62 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $0.59 by $0.03. The company had revenue of $525.20 million for the quarter, compared to analyst estimates of $525.99 million. Enovis had a positive return on equity of 4.06% and a negative net margin of 4.73%. Enovis's revenue for the quarter was up 22.6% compared to the same quarter last year. During the same period in the previous year, the firm earned $0.61 earnings per share. On average, research analysts predict that Enovis Co. will post 2.7 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

ENOV has been the subject of a number of research reports. Evercore ISI lowered their price objective on shares of Enovis from $70.00 to $62.00 and set an "outperform" rating for the company in a research note on Tuesday, July 2nd. JPMorgan Chase & Co. decreased their target price on shares of Enovis from $53.00 to $50.00 and set a "neutral" rating on the stock in a research report on Thursday, August 8th. Finally, Needham & Company LLC dropped their price target on shares of Enovis from $82.00 to $65.00 and set a "buy" rating for the company in a research report on Thursday, August 8th. One research analyst has rated the stock with a hold rating and eight have assigned a buy rating to the company's stock. Based on data from MarketBeat, the company presently has a consensus rating of "Moderate Buy" and a consensus target price of $69.13.

About Enovis

Enovis Corporation operates as a medical technology company focus on developing clinically differentiated solutions worldwide. It also manufactures and distributes medical devices which are used for reconstructive surgery, rehabilitation, pain management, and physical therapy. The company operates through Prevention and Recovery, and Reconstructive segments.